Quarterly ResultMay 7, 2026, 06:13 AM
Pharming Group Q1 Revenue $72.4M; Joenja® +34%
AI Summary
Pharming Group reported Q1 2026 total revenues of US$72.4 million, an 8% decrease year-over-year. Joenja® revenue grew 34% to US$14.1 million, driven by strong patient uptake, while RUCONEST® revenue declined 15% to US$58.4 million due to anticipated inventory drawdowns and market exits. The company reaffirmed its 2026 total revenue guidance of US$405 million - US$425 million and achieved significant regulatory milestones for Joenja®, including approval in Japan and a positive CHMP opinion in Europe, alongside resubmitting its pediatric sNDA to the FDA.
Key Highlights
- Q1 2026 total revenues were US$72.4 million, an 8% decrease YoY.
- Joenja® revenue increased 34% to US$14.1 million in Q1 2026.
- RUCONEST® revenue decreased 15% to US$58.4 million in Q1 2026.
- Net loss for Q1 2026 was US$5.2 million, compared to US$14.9 million in Q1 2025.
- Generated positive net cash flow from operations of US$2.0 million in the quarter.
- Reaffirmed 2026 total revenue guidance of US$405 million - US$425 million (8% - 13% growth).
- Joenja® approved in Japan for APDS patients aged 4 and older.
- Resubmitted pediatric sNDA to the FDA for Joenja® for highest doses.